Subscribe
img_1651
22 October 2019AmericasSarah Morgan

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSPN 19: choose your IP strategy wisely, warn IP experts
24 October 2019   Choosing the right IP strategy is crucial for companies, but constrained budgets and picking the wrong partners are all factors that can steer companies off the correct path.
Biotechnology
LSPN Connect: Protecting biologics at home and abroad
4 September 2020   Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Americas
LSPN 19: choose your IP strategy wisely, warn IP experts
24 October 2019   Choosing the right IP strategy is crucial for companies, but constrained budgets and picking the wrong partners are all factors that can steer companies off the correct path.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Biotechnology
LSPN Connect: Protecting biologics at home and abroad
4 September 2020   Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern.

More on this story

Americas
LSPN 19: choose your IP strategy wisely, warn IP experts
24 October 2019   Choosing the right IP strategy is crucial for companies, but constrained budgets and picking the wrong partners are all factors that can steer companies off the correct path.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Biotechnology
LSPN Connect: Protecting biologics at home and abroad
4 September 2020   Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?